Cerebrolysin and Recovery After Stroke (CARS)

Autor: Alla Guekht, Herbert Moessler, Wolf-Dieter Heiss, Ovidiu Bajenaru, Johannes C. Vester, Edith Doppler, Volker Hoemberg, Dafin F. Muresanu, Volker W. Rahlfs, Christian Dinu Popescu, Dieter Meier
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Male
medicine.medical_specialty
medicine.medical_treatment
Original Contributions
Clinical Sciences
recovery of function
Placebo
rehabilitation
randomized
double-blind
placebo-controlled trial

03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Double-Blind Method
Multicenter trial
medicine
Clinical endpoint
Humans
030212 general & internal medicine
Prospective Studies
Amino Acids
Prospective cohort study
Stroke
Aged
Advanced and Specialized Nursing
Rehabilitation
business.industry
Cerebrolysin
Middle Aged
medicine.disease
stroke
Confidence interval
Neuroprotective Agents
Treatment Outcome
chemistry
Anesthesia
Physical therapy
ComputingMethodologies_DOCUMENTANDTEXTPROCESSING
Female
Neurology (clinical)
Cardiology and Cardiovascular Medicine
business
030217 neurology & neurosurgery
Zdroj: Stroke; a Journal of Cerebral Circulation
ISSN: 1524-4628
0039-2499
Popis: Supplemental Digital Content is available in the text.
Background and Purpose— The aim of this trial was to investigate whether stroke patients who receive Cerebrolysin show improved motor function in the upper extremities at day 90 compared with patients who receive a placebo. Methods— This study was a prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Patients were treated with Cerebrolysin (30 mL/d) or a placebo (saline) once daily for 21 days, beginning at 24 to 72 hours after stroke onset. The patients also participated in a standardized rehabilitation program for 21 days that was initiated within 72 hours after stroke onset. The primary end point was the Action Research Arm Test score on day 90. Results— The nonparametric effect size on the Action Research Arm Test score on day 90 indicated a large superiority of Cerebrolysin compared with the placebo (Mann–Whitney estimator, 0.71; 95% confidence interval, 0.63–0.79; P
Databáze: OpenAIRE